A detailed history of Capital Research Global Investors transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Capital Research Global Investors holds 7,909,114 shares of DNLI stock, worth $165 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
7,909,114
Previous 7,126,533 10.98%
Holding current value
$165 Million
Previous $165 Million 39.23%
% of portfolio
0.05%
Previous 0.04%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$20.96 - $31.05 $16.4 Million - $24.3 Million
782,581 Added 10.98%
7,909,114 $230 Million
Q2 2024

Aug 13, 2024

BUY
$14.96 - $23.22 $16.1 Million - $25 Million
1,076,576 Added 17.79%
7,126,533 $165 Million
Q1 2024

May 14, 2024

BUY
$15.83 - $23.35 $49.7 Million - $73.3 Million
3,140,429 Added 107.94%
6,049,957 $124 Million
Q4 2023

Feb 13, 2024

BUY
$16.2 - $23.18 $473,121 - $676,971
29,205 Added 1.01%
2,909,528 $62.4 Million
Q3 2023

Nov 13, 2023

BUY
$20.63 - $30.17 $880,302 - $1.29 Million
42,671 Added 1.5%
2,880,323 $59.4 Million
Q2 2023

Aug 11, 2023

BUY
$23.37 - $32.96 $8.62 Million - $12.2 Million
368,828 Added 14.94%
2,837,652 $83.7 Million
Q1 2023

May 15, 2023

BUY
$21.91 - $32.67 $4.56 Million - $6.8 Million
208,182 Added 9.21%
2,468,824 $56.9 Million
Q4 2022

Feb 14, 2023

BUY
$26.28 - $33.92 $57.1 Million - $73.7 Million
2,172,875 Added 2475.73%
2,260,642 $62.9 Million
Q3 2022

Nov 14, 2022

BUY
$25.97 - $38.53 $2.28 Million - $3.38 Million
87,767 New
87,767 $2.65 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.81B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Capital Research Global Investors Portfolio

Follow Capital Research Global Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Research Global Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital Research Global Investors with notifications on news.